Abstract
The COVID-19 pandemic unexpectedly stopped the steady life and enhanced environmental quality. To apprehend the transmission of COVID-19 and the improvement of air quality, we have studied air quality indicators (PM2.5, PM10, AQI, and NO2), CO2 emission, and climate variables (temperature, relative humidity, rainfall, and wind velocity) in the extremely polluted and densely populated Southeast Asian megacity Dhaka, Bangladesh from March to June 2020. The Kendall and Spearman correlations were chosen to test the connotation of air quality and climate variables with COVID-19 morbidity and mortality. The average concentrations of PM2.5, PM10, and CO2 were 65.0 ± 37.9 and 87.1 ± 52.8 µm m-3, and 427 ± 11.8 ppm, respectively. The average PM2.5 and PM10 drastically reduced up to 62% during COVID-19 lockdown in Dhaka comparing with March 2020 (before lockdown). Comparing with the same period in 2019, PM2.5 reduced up to 33.5%. The average NO2 concentration was 35.0 µmol m-2 during the lockdown period in April, whereas 175.0 µmol m-2 during March (before lockdown). A significant correlation was observed between COVID-19 cases and air quality indicators. A strong correlation was obtained between climate variables and the total number of COVID-19 morbidity and mortality representing a favorable condition for spreading the virus. Our study will be very expedient for policymakers to establish a mechanism for air pollution mitigation based on scientific substantiation, and also will be an essential reference for the advance research to improve urban air quality and the transmission of the SARS-CoV-2 virus in the tropical nations.
Highlights
COVID-19 lockdown drastically reduced PM2.5 and PM10 concentrations up to 62%.
During lockdown, NO2 emission abridged up to 80%, CO2 emission dropped by 2-4%.
Climate variables revealed strong correlation with COVID-19 morbidity and mortality.
COVID-19 cases and mortality had significant correlation with air quality indicators.
Knowledge from enormous improved air quality will be transmitted to the policy execution.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
Not applicanle
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not application for this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available upon request
